GSK (NYSE:GSK) Announces Earnings Results, Beats Estimates By $0.15 EPS

GSK (NYSE:GSK) released its earnings results on Wednesday. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15, Zacks reports. GSK had a return on equity of 50.62% and a net margin of 7.97%. GSK updated its FY 2025 guidance to 2.090-2.130 EPS.

GSK Stock Performance

Shares of NYSE:GSK traded up $2.81 during trading on Wednesday, reaching $37.65. The company had a trading volume of 5,331,486 shares, compared to its average volume of 4,314,579. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock’s fifty day moving average price is $34.10 and its 200 day moving average price is $37.60. The firm has a market capitalization of $78.04 billion, a price-to-earnings ratio of 24.43, a price-to-earnings-growth ratio of 1.38 and a beta of 0.64.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com cut shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Six research analysts have rated the stock with a hold rating, one has given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.